Literature DB >> 26888370

Safety of stress testing in patients with elevated cardiac biomarkers: Are all modalities created equal?

Rami Doukky1,2, Yasmeen Golzar3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26888370     DOI： 10.1007/s12350-016-0440-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN： 1071-3581            Impact factor:   5.952


× No keyword cloud information.
  16 in total

1.  Safety of vasodilator stress myocardial perfusion imaging in patients with elevated cardiac biomarkers.

Authors:  Mridula Rai; Alan W Ahlberg; Julianna Marwell; Waseem Chaudhary; John A Savino; Eric L Alter; Milena J Henzlova; W Lane Duvall
Journal:  J Nucl Cardiol       Date:  2016-02-22       Impact factor: 5.952

2.  Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.

Authors:  Rami Doukky; Adebayo Olusanya; Raj Vashistha; Abhimanyu Saini; Ibtihaj Fughhi; Khaled Mansour; Abiy Nigatu; Kara Confer; Shannon A Sims
Journal:  J Nucl Cardiol       Date:  2015-04-24       Impact factor: 5.952

3.  Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.

Authors:  Afshin Farzaneh-Far; Linda K Shaw; Allison Dunning; Jorge D Oldan; Christopher M O'Connor; Salvador Borges-Neto
Journal:  J Nucl Cardiol       Date:  2015-05-19       Impact factor: 5.952

4.  Safety of early intravenous dipyridamole technetium 99m sestamibi SPECT myocardial perfusion imaging after uncomplicated first myocardial infarction. Early Post MI IV Dipyridamole Study (EPIDS).

Authors:  G V Heller; K A Brown; R J Landin; S B Haber
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

5.  Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study.

Authors:  J Lette; J L Tatum; S Fraser; D D Miller; D D Waters; G Heller; E B Stanton; H S Bom; J Leppo; S Nattel
Journal:  J Nucl Cardiol       Date:  1995 Jan-Feb       Impact factor: 5.952

6.  The prognostic value of regadenoson myocardial perfusion imaging.

Authors:  Fadi G Hage; Gopal Ghimire; Davis Lester; Joshua Mckay; Steven Bleich; Stephanie El-Hajj; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2015-02-14       Impact factor: 5.952

7.  Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial.

Authors:  Ami E Iskandrian; Timothy M Bateman; Luiz Belardinelli; Brent Blackburn; Manuel D Cerqueira; Robert C Hendel; Hsiao Lieu; John J Mahmarian; Ann Olmsted; S Richard Underwood; João Vitola; Whedy Wang
Journal:  J Nucl Cardiol       Date:  2007 Sep-Oct       Impact factor: 5.952

8.  Role of adenosine thallium-201 tomography for defining long-term risk in patients after acute myocardial infarction.

Authors:  J J Mahmarian; A C Mahmarian; G F Marks; C M Pratt; M S Verani
Journal:  J Am Coll Cardiol       Date:  1995-05       Impact factor: 24.094

9.  Safety of dobutamine-atropine stress myocardial perfusion scintigraphy.

Authors:  A Elhendy; R Valkema; R T van Domburg; J J Bax; P R Nierop; J H Cornel; M L Geleijnse; A E Reijs; E P Krenning; J R Roelandt
Journal:  J Nucl Med       Date:  1998-10       Impact factor: 10.057

10.  Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.

Authors:  John J Mahmarian; Leif E Peterson; Jiaqiong Xu; Manuel D Cerqueira; Ami E Iskandrian; Timothy M Bateman; Gregory S Thomas; Faisal Nabi
Journal:  J Nucl Cardiol       Date:  2014-10-07       Impact factor: 5.952
View more
  1 in total

Review 1.  Review of cardiovascular imaging in the Journal of Nuclear Cardiology in 2017. Part 2 of 2: Myocardial perfusion imaging.

Authors:  Fadi G Hage; Wael A AlJaroudi
Journal:  J Nucl Cardiol       Date:  2018-04-16       Impact factor: 5.952
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.